|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
After bruising her shoulder from a fall in the spring of 2009, Ayse Sule Sevin, a native of Turkey, noticed that the bruise was not going away. She visited a doctor in hopes of finding out what was wrong, but the doctor was unable to determine the problem. A few months later, Sevin began experiencing chest pain and bleeding gums. Although her doctor prescribed medications to treat these symptoms, her problems continued to worsen. Finally, in October 2009, doctors diagnosed …
Vaxil BioTherapeutics Initiates Phase 1/2 Clinical Trial Of ImMucin - Vaxil Biotherapeutics, a vaccine development company, has begun recruiting multiple myeloma patients for a Phase 1/2 clinical trial for its therapeutic vaccine ImMucin. Patients in the clinical trial will receive between six and twelve injections of ImMucin over three to six months. Researchers will follow up with patients for an additional six months. The clinical trial, which will evaluate the safety of ImMucin, will be held in Israel, where …
| Brand Name: | ImMucin |
| Generic Name: | |
| Code Name: | |
| Company: | Vaxil BioTherapeutics |
| FDA Clinical Phase: | 1/2 |
Description:
ImMucin is a vaccine designed to stimulate the patient’s own immune system to kill cancer cells. ImMucin is a synthetic version of the important region of the MUC1 protein, which …
| Brand Name: | |
| Generic Name: | |
| Code Name: | BI-505 |
| Company: | BioInvent |
| FDA Clinical Phase: | 1 |
Description:
BI-505 is a fully human antibody that causes cell death. It binds to the protein ICAM-1 (CD54), which is more common in tumors than in normal tissue. BI-505 may therefore be …
The 10-year follow-up results of a Phase 2 trial suggest that thalidomide increases the median time to disease progression in smoldering multiple myeloma patients who respond to treatment.
However, researchers also observed an increased rate of side effects compared to earlier results. They therefore do not recommend the use of thalidomide in smoldering myeloma patients.
Approximately 10 to 15 percent of all myeloma patients have smoldering myeloma, a slow-growing form of the disease that often appears without symptoms. Approximately 73 …
A recent study showed that maintenance therapy with thalidomide and interferon delayed progression, but did not extend survival, in elderly multiple myeloma patients. Additionally, the thalidomide-interferon maintenance therapy caused slightly more side effects than maintenance therapy with interferon alone.
Previous studies have indicated that in younger patients, maintenance therapy with thalidomide (Thalomid) after stem cell transplantation resulted in increased progression-free survival time in all trials and in increased overall survival time in two out of five trials (see related …
A recent study reported that long-term surviving myeloma patients are generally younger and have received and responded well to treatment with conventional chemotherapy. Dr. M. Kraj of the Institute of Hematology and Transfusion Medicine in Warsaw, Poland, presented the findings at the European Hematology Association (EHA) meeting in Barcelona last month.
Dr. Kraj and her colleagues aimed to identify common clinical and laboratory features in long-term surviving myeloma patients, as these may assist physicians in determining an accurate prognosis for …
